{"id":"W2851615044","doi":"10.1136/esmoopen-2018-000364","title":"Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Alectinib; Medicine; Crizotinib; Lung cancer; Tolerability; Internal medicine; Quality of life (healthcare); ALK inhibitor; Performance status; Clinical endpoint; Oncology; Cancer; Adverse effect; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006687829,0.0002108663,0.0005908802,0.0001980703,0.00009577119,0.00001996246,0.0001431349,0.00002353278,0.00008336623],"category_scores_gemma":[0.00002402689,0.0001549646,0.00003333172,0.0007068925,0.00008308491,0.0001303749,0.0001222356,0.0001227769,0.000001536856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002269336,"about_ca_system_score_gemma":0.0003409649,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.07551273,"about_ca_topic_score_gemma":0.1560146,"domain_scores_codex":[0.9984857,0.00005532989,0.0005118005,0.0004086897,0.0002599234,0.0002785044],"domain_scores_gemma":[0.9988739,0.00003869171,0.0003783782,0.000354113,0.0002500075,0.0001048871],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002315651,0.01234551,0.9685339,0.00001932351,0.0003716646,0.00007056115,0.01280848,0.00001070778,0.00001442079,3.597231e-7,0.0001592105,0.003350173],"study_design_scores_gemma":[0.0287848,0.01325334,0.9553359,0.0001402754,0.0003567815,4.753618e-7,0.00149203,0.00002240665,0.0003594132,3.832943e-7,0.00009156945,0.000162644],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920694,0.000009144578,0.000003988057,0.00007946706,0.00008114721,0.00407896,0.00008172254,0.00001156647,0.003584667],"genre_scores_gemma":[0.9984615,0.000002786895,0.0002976446,0.0001964314,0.00001482781,0.0004274476,0.00009034442,0.0000319541,0.0004770064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08050188,"threshold_uncertainty_score":0.9306435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01323684407167879,"score_gpt":0.3460740368954021,"score_spread":0.3328371928237233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}